Inclusion Criteria:

1. Histology and staging of the disease

- Histologically or cytologically confirmed NSCLC; histology may include: large
cell, squamous cell or adenocarcinoma but no SCLC

- Resectable or unresectable NSCLC stage II (T1-2 N1, T3 N0) or stage IIIa (T1-2
N2 or T3 N1-2) or stage IIIb (T1-3 N3 or T4 N0-3)

- Measurable disease (bidimensionally or unidimensionally according to WHO
criteria)

2. General conditions

- Karnofsky Status > 70, if age > 70 years → PS > 70

- Adequate hematological function (Hb > 10 g/dl, ANC > 2.0 x 109/L, platelets >
100 x 109/L)

- Adequate renal and hepatic functions: total bilirubin < 1 x upper normal limit
(UNL), serum creatinine < 1 x UNL, in case of limit value the creatinine
clearance should be > 60 ml/min, ASAT and ALAT < 2.5 x UNL, alkaline phosphatase
< 5 x UNL.

Exclusion Criteria:

1. Diagnosis

- Evidence of brain metastases or other distant metastasis equivalent to stage IV
disease

- History of prior malignancies, except for curatively treated non-melanoma skin
cancer or in situ carcinoma of the cervix or other curatively treated cancer
with no evidence of disease for at least five years

- Other serious concomitant illness or medical condition:

- Congestive heart failure or angina pectoris, except if medically
controlled, history of myocardial infarction within 1 year from study
entry, uncontrolled hypertension or arrhythmia

- History of significant neurologic or psychiatric disorders, including
dementia or seizure

- Active infection requiring i.v. Antibiotics

- Active ulcer, unstable diabetes mellitus or other contraindications to
corticotherapy

- Hepatic function abnormality: ASAT and/or ALAT > 1.5 x UNL associated with
alkaline phosphatase > 2.5 x UNL

- Current peripheral neuropathy WHO grade > 2

2. Prior or concurrent therapy

- Prior chemotherapy or immunotherapy for NSCLC, including neoadjuvant or adjuvant
treatment

- Prior surgery or radiotherapy for NSCLC

- Concurrent treatment with other experimental drugs, unapproved medical
procedures or other anticancer therapy

3. General conditions

- Pregnant or lactating patients

- Patients (M/F) with reproductive potential not implementing adequate
contraceptive measurements

The above information is not intended to contain all considerations relevant to a
patient's potential participation in a clinical trial.